Buddy Lyons
Value, long/short equity, contrarian, growth

Simulations Plus: Several Catalysts Provide Favorable Risk-Reward

Although the ongoing sea change in healthcare is primarily related to delivery, every industry within the sector is affected. Reducing costs and time-to-market is particularly crucial in drug development where new chemical entity discovery has traditionally been hit and miss, and where big pharma has wasted billions in R&D dollars. The companies have as much admitted the inefficiencies of their own R&D and development by linking themselves strategically with CROs.

We believe this provides an opportunity for companies who can effectively fill the drug discovery and development gap by reducing time to discovery of useful molecules, in addition to predicting the activity of molecules in vivo in order to reduce the time and cost of clinical trials and of the...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details